GleamWall
中文EN

ELTX Elicio Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1601485 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY22.1%
TTM EPS YoY41.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-315.3%
ROA-105.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets52.4%
Debt / equity0.51x
Current ratio3.43x
Interest coverage-24.46x

Cash quality & payout

Operating cash flow / net income1.03x
Accruals ratio3.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$4.89M$6.81M$6.76M$5.08M$5.04M$7.01M$7.78M$10.71M
SG&A expense$3.56M$3.62M$3.85M$3.76M$3.01M$3.08M$2.96M$2.77M
Operating income-$8.45M-$10.43M-$10.60M-$8.84M-$8.04M-$10.09M-$10.74M-$13.48M
Interest expense$413,000$410,000$407,000$337,000$426,000$194,000$176,000$234,000
Pretax income-$7.92M——-$7.72M-$10.08M———
Income tax$55,000$0$0$0$0$0$0$0
Net income-$7.98M-$8.22M-$11.82M-$7.72M-$10.08M-$10.56M-$11.21M-$14.00M
EBITDA-$8.45M-$10.33M-$10.56M-$8.79M-$7.95M-$9.99M-$10.68M-$13.39M
EPS (basic)-0.30-0.43-0.65—-0.60-0.66-0.87—
EPS (diluted)-0.30-0.43-0.65—-0.60-0.66-0.87—
Weighted avg. shares (diluted)26.29M19.24M18.21M—16.69M16.06M12.95M—
Balance sheet
Cash & equivalents$30.90M$23.48M$14.95M$18.56M$20.61M$22.09M$18.35M$19.49M
Current assets$34.03M$25.48M$16.20M$19.31M$21.46M$22.60M$20.93M$20.69M
PP&E, net$182,000$213,000$249,000$295,000$328,000$377,000$430,000$483,000
Total assets$39.60M$31.33M$22.69M$25.86M$28.28M$29.53M$28.14M$28.18M
Current liabilities$9.93M$9.20M$7.23M$8.11M$6.51M$9.92M$11.41M$11.52M
Short-term debt$2.48M——$0————
Long-term debt$7.16M$9.54M$9.47M$9.41M$9.72M$9.34M—$20.03M
Total debt$9.63M$9.54M$9.47M$9.41M$9.72M$9.34M—$20.03M
Total liabilities$20.75M$23.39M$24.13M$24.23M$24.47M$27.69M$19.24M$39.49M
Shareholders' equity$18.85M$7.94M-$1.44M$1.64M$3.82M$1.83M$8.90M-$11.31M
Net debt-$21.27M-$13.95M-$5.47M-$9.16M-$10.89M-$12.75M—$542,000
Shares outstanding28.31M21.90M18.64M17.80M17.26M16.26M15.97M11.03M
Cash flow statement
Operating cash flow-$10.36M-$8.16M-$11.64M-$6.80M-$11.09M-$8.95M-$10.12M-$8.74M
Capital expenditure———$16,000$0——$45,000
Free cash flow———-$6.81M-$11.09M——-$8.79M
Investing cash flow———-$16,000$0$0$0-$45,000
Financing cash flow$17.79M$16.51M$8.03M$4.86M$9.57M$11.93M$10.33M$227,000
Depreciation & amortization$0$100,000$46,000$49,000$100,000$100,000$53,000$85,000
Stock-based compensation$1.11M$935,000$868,000$772,000$698,000$710,000$517,000$464,000

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.